| [1] |
Popa MT, Noditi A, Peleaşa TM, et al. Breast cancer: a heterogeneous pathology. prognostic and predictive factors-a narrative review[J]. Chirurgia, 2025, 120(1): 32. doi:10.21614/chirurgia.3100
|
| [2] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-63. doi:10.3322/caac.21834
|
| [3] |
Rajput S, Sharma PK, Malviya R. Biomarkers and treatment strategies for breast cancer recurrence[J]. Curr Drug Targets, 2023, 24(15): 1209-20. doi:10.2174/0113894501258059231103072025
|
| [4] |
Park M, Kim D, Ko S, et al. Breast cancer metastasis: mechanisms and therapeutic implications[J]. Int J Mol Sci, 2022, 23(12): 6806. doi:10.3390/ijms23126806
|
| [5] |
Kumar S, Ziegler Y, Plotner BN, et al. Resistance to FOXM1 inhibitors in breast cancer is accompanied by impeding ferroptosis and apoptotic cell death[J]. Breast Cancer Res Treat, 2024, 208(2): 307-20. doi:10.1007/s10549-024-07420-9
|
| [6] |
Zagami P, Carey LA. Triple negative breast cancer: Pitfalls and progress[J]. npj Breast Cancer, 2022, 8: 95. doi:10.1038/s41523-022-00468-0
|
| [7] |
Zhu SL, Wu YZ, Song B, et al. Recent advances in targeted strategies for triple-negative breast cancer[J]. J Hematol Oncol, 2023, 16(1): 100. doi:10.1186/s13045-023-01497-3
|
| [8] |
Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149(5): 1060-72. doi:10.1016/j.cell.2012.03.042
|
| [9] |
Huang GQ, Cai YW, Ren MH, et al. Salidroside sensitizes Triple-negative breast cancer to ferroptosis by SCD1-mediated lipogenesis and NCOA4-mediated ferritinophagy[J]. J Adv Res, 2025, 74: 589-607. doi:10.1016/j.jare.2024.09.027
|
| [10] |
Lorito N, Subbiani A, Smiriglia A, et al. FADS1/2 control lipid metabolism and ferroptosis susceptibility in triple-negative breast cancer[J]. EMBO Mol Med, 2024, 16(7): 1533-59. doi:10.1038/s44321-024-00090-6
|
| [11] |
Liu WH, Jiang CJ, Ma Y, et al. The impact of ferroptosis and ferroptosis-related non-coding RNAs on breast cancer progression[J]. Front Cell Dev Biol, 2024, 12: 1506492. doi:10.3389/fcell.2024.1506492
|
| [12] |
Sun T, Zhang PH, Zhang QY, et al. Transcriptome analysis reveals PRKCA as a potential therapeutic target for overcoming cisplatin resistance in lung cancer through ferroptosis[J]. Heliyon, 2024, 10(10): e30780. doi:10.1016/j.heliyon.2024.e30780
|
| [13] |
Lei G, Zhuang L, Gan BY. The roles of ferroptosis in cancer: Tumor suppression, tumor microenvironment, and therapeutic interventions[J]. Cancer Cell, 2024, 42(4): 513-34. doi:10.1016/j.ccell.2024.03.011
|
| [14] |
Cortez MA, Ivan C, Zhou P, et al. microRNAs in cancer: from bench to bedside[J]. Adv Cancer Res, 2010, 108: 113-57.
|
| [15] |
Ho PTB, Clark IM, Le LTT. microRNA-based diagnosis and therapy[J]. Int J Mol Sci, 2022, 23(13): 7167. doi:10.3390/ijms23137167
|
| [16] |
Bartel DP. microRNAs genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2): 281-97. doi:10.1016/s0092-8674(04)00045-5
|
| [17] |
Huang LH, Wang XL, Zhang SY, et al. FAM46B inhibits CS-induced oxidative stress and ferroptosis in bronchial epithelial cells via KLHL24[J]. Int Immunopharmacol, 2025, 165: 115465. doi:10.1016/j.intimp.2025.115465
|
| [18] |
Abdi E, Latifi-Navid S, Latifi-Navid H. LncRNA polymorphisms and breast cancer risk[J]. Pathol Res Pract, 2022, 229: 153729. doi:10.1016/j.prp.2021.153729
|
| [19] |
Filippova EA, Pronina IV, Lukina SS, et al. LncRNA interactomes and co-methylation in breast cancer regulation[J]. Biomol Biomed, 2025, 25(11): 2481-95. doi:10.17305/bb.2025.12333
|
| [20] |
Li Y, Zeng QA, Qiu JL, et al. miR-183-5p promotes proliferation, metastasis and angiogenesis in breast cancer cells through negatively regulating four and a half LIM protein 1[J]. J Breast Cancer, 2020, 23(4): 355-72. doi:10.4048/jbc.2020.23.e47
|
| [21] |
Jin L, Luo Y, Zhao YC, et al. miR-183-5p promotes tumor progression of osteosarcoma and predicts poor prognosis in patients[J]. Cancer Manag Res, 2021, 13: 805-14. doi:10.2147/cmar.s285909
|
| [22] |
Feng YH, Wang K, Qin MC, et al. miR-183-5p promotes migration and invasion of prostate cancer by targeting TET1[J]. BMC Urol, 2023, 23(1): 116. doi:10.1186/s12894-023-01286-7
|
| [23] |
Han C, Mo KN, Jiang L, et al. miR-183-5p promotes proliferation, invasion, and glycolysis of thyroid carcinoma cells by targeting FOXO1[J]. Mol Cell Biochem, 2022, 477(4): 1195-206. doi:10.1007/s11010-022-04357-9
|
| [24] |
Chen JH, Zhou DB, Liao HY, et al. miR-183-5p regulates ECM and EMT to promote non-small cell lung cancer progression by targeting LOXL4[J]. J Thorac Dis, 2023, 15(4): 1734-48. doi:10.21037/jtd-23-329
|
| [25] |
Shu LZ, Li XY, Liu ZL, et al. Bile exosomal miR-182/183-5p increases cholangiocarcinoma stemness and progression by targeting HPGD and increasing PGE2 generation[J]. Hepatology, 2024, 79(2): 307-22. doi:10.1097/hep.0000000000000437
|
| [26] |
Vermeer MCSC, Bolling MC, Bliley JM, et al. Gain-of-function mutation in ubiquitin ligase KLHL24 causes desmin degradation and dilatation in hiPSC-derived engineered heart tissues[J]. J Clin Investig, 2021, 131(17): e140615. doi:10.1172/jci140615
|
| [27] |
Jiang G, Jin P, Xiao X, et al. Identification and validation of a novel CD8+ T cell-associated prognostic model based on ferroptosis in acute myeloid leukemia[J]. Front Immunol, 2023, 14: 1149513. doi:10.3389/fimmu.2023.1149513
|
| [28] |
Zhou CT, Li AH, Liu S, et al. Identification of an 11-autophagy-related-gene signature as promising prognostic biomarker for bladder cancer patients[J]. Biology, 2021, 10(5): 375. doi:10.3390/biology10050375
|
| [29] |
Zhao DH, Hou F, Li MJ, et al. A novel KLHL6/KLHL24 intergenic region-NTRK3 fusion in a patient with lung squamous cell carcinoma[J]. Lung Cancer, 2021, 155: 193-5. doi:10.1016/j.lungcan.2021.03.001
|